Journal Article

AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double‐blind, efficacy, and safety study

Lei, Alejhandra, Safy‐Khan, Mary, Öberg, Lisa, Kapetanovic, Meliha, Keen, Christina, Etal, Damla, Axelsson, Lena T., Olsson, Richard, Nemes, Szilárd, Taib, Ziad, Tubergen, Astrid, Belfield, Graham, Vikman, Kerstin, Vonkeman, Harald, Samuelsson, Sara, Dillmann, Inken, Kaan, Ellen, Astbury, Carol, Moghadam, Marjan Ghiti, Einarsson, Jon Thorkell, Platt, Adam, Svanberg, Petter, Jacobs, J. W. G., Ekwall, Anna‐Karin, Laar, Jacob M., Hermans, Kasper, Almquist, Joachim, Belvisi, Maria G., Gjertsson, Inger, Edman, Karl, Prothon, Susanne, Angermann, Bastian R., Berntsson, Pia, Dainty, Ian, Myrbäck, Tove Hegelund

2023

Overview

Oral corticosteroid use is limited by side effects, some caused by off‐target actions on the mineralocorticoid receptor that disrupt electrolyte balance. AZD9567 is a selective, nonsteroidal glucocorticoid receptor modulator. The efficacy, safety, and tolerability of AZD9567 and prednisolone were assessed in a phase IIa study. Anti‐inflammatory mechanism of action was also evaluated in vitro in monocytes from healthy donors. In this randomized, double‐blind, parallel‐group, multicenter study, patients with active rheumatoid arthritis were randomized 1:1 to AZD9567 40 mg or prednisolone 20 mg once daily orally for 14 days. The primary end point was change from baseline in DAS28‐CRP at day 15. Secondary end points included components of DAS28‐CRP, American College of Rheumatology (ACR) response criteria (ACR20, ACR50, and ACR70), and safety end points, including serum electrolytes. Overall, 21 patients were randomized to AZD9567 (n = 11) or prednisolone (n = 10), and all completed the study. As anticipated, AZD9567 had a similar efficacy profile to prednisolone, with no clinically meaningful (i.e., >1.0) difference in change from baseline to day 15 in DAS28‐CRP between AZD9567 and prednisolone (least‐squares mean difference: 0.47, 95% confidence interval: −0.49 to 1.43). Similar results were observed for the secondary efficacy end points. In vitro transcriptomic analysis showed that anti‐inflammatory responses were similar for AZD9567, prednisolone, and dexamethasone. Unlike prednisolone, AZD9567 had no effect on the serum sodium:potassium ratio. The safety profile was not different from that of prednisolone. Larger studies of longer duration are required to determine whether AZD9567 40 mg may in the future be an alternative to prednisolone in patients with inflammatory disease.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
• Subject: Anti-Inflammatory Agents - therapeutic use / Antirheumatic Agents - therapeutic use / Arthritis, Rheumatoid - drug therapy / Cytokines / Dexamethasone / Double-Blind Method / Drug dosages / Electrolyte balance / Electrolytes / Glucocorticoid receptors / Glucose / Humans / Hypothesis testing / Inflammatory diseases / Methotrexate - therapeutic use / Mineralocorticoid receptors / Monocytes / Pharmacokinetics / Prednisolone / Prednisolone - adverse effects / Rheumatoid arthritis / Rheumatology / Safety / Steroids / Transcriptomics / Treatment Outcome